Cargando…

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661979/ https://www.ncbi.nlm.nih.gov/pubmed/31413572 http://dx.doi.org/10.2147/IJN.S207276

Ejemplares similares

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015)

PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse
por: Konishi, Hiroaki, et al.
Publicado: (2012)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Publicado: (2013)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin [Corrigendum]
Publicado: (2021)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
Publicado: (2015)

CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Publicado: (2017)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Corrigendum to “Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer's disease” [EBioMedicine 2 (2015) 294–305]
por: Zhang, Liang, et al.
Publicado: (2019)

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]
Publicado: (2013)

Tat-Functionalized Liposomes for the Treatment of Meningitis: An in vitro Study [Corrigendum]
Publicado: (2020)

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
por: de Man, Femke M., et al.
Publicado: (2018)

Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma [Corrigendum]
Publicado: (2017)

Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC [Corrigendum]
Publicado: (2021)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Modulated electro-hyperthermia-enhanced liposomal drug uptake by cancer cells [Corrigendum]
Publicado: (2019)

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
por: Mathijssen, R H J, et al.
Publicado: (2002)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Pharmacokinetics and Anti-Tumor Efficacy of PEGylated Liposomes Co-Loaded with Cisplatin and Mifepristone
por: Ocaña-Arakachi, Karen, et al.
Publicado: (2023)

Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes [Corrigendum]
Publicado: (2014)

Application of Multifunctional Targeting Epirubicin Liposomes in the Treatment of Non-Small-Cell Lung Cancer [Corrigendum]
Publicado: (2021)

Insights into the antibacterial mechanism of PEGylated nano-bacitracin A against Streptococcus pneumonia: both penicillin-sensitive and penicillin-resistant strains [Corrigendum]
Publicado: (2019)

Emodin-Conjugated PEGylation of Fe(3)O(4) Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer [Corrigendum]
Publicado: (2022)

Insights into the Antibacterial Mechanism of PEGylated Nano-Bacitracin A Against Streptococcus pneumonia: Both Penicillin-Sensitive and Penicillin-Resistant Strains [Corrigendum]
Publicado: (2022)

The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
por: Pan, Xing Qing, et al.
Publicado: (2006)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Corrigendum to “Precision Medicine in Assisted Conception: A Multicenter Observational Treatment Cohort Study of the Annexin A5 M2 Haplotype as a Biomarker for Antithrombotic Treatment to Improve Pregnancy Outcome” [EBioMedicine 10 (2016) 299-305]
por: Fishel, Simon, et al.
Publicado: (2016)

Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes
por: Yuan, Jiani, et al.
Publicado: (2017)

Corrigendum to “The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation”
por: Samy, Kannan P., et al.
Publicado: (2018)

Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines – in vitro studies [Corrigendum]
Publicado: (2015)

Steady Augmentation of Anti-Osteoarthritic Actions of Rapamycin by Liposome-Encapsulation in Collaboration with Low-Intensity Pulsed Ultrasound [Corrigendum]
Publicado: (2021)

Anti-Oxidative, Anti-Apoptotic, and M2 Polarized DSPC Liposome Nanoparticles for Selective Treatment of Atherosclerosis [Corrigendum]
Publicado: (2023)

Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug
por: Song, Shiwen, et al.
Publicado: (2023)

Corrigendum to “New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy”
por: Guo, Qiujun, et al.
Publicado: (2018)

GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma [Corrigendum]
Publicado: (2022)

Transparent and credible practices under the microscope: a response to comments on Ihle et al.
por: Winney, Isabel S., et al.
Publicado: (2017)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes
por: Zhai, Bingtao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j7c9hscn9pr0bqfaela09m5sm1